Literature DB >> 12174159

Value of urinary prophylaxis with methenamine in gynecologic surgery.

Hjalmar A Schiøtz1, Kristian Guttu.   

Abstract

BACKGROUND: There is a high risk of postoperative bacteriuria and urinary tract infection after gynecologic surgery. Postoperative asymptomatic bacteriuria often disappears without treatment, but 15-20% of patients still require treatment for postoperative urinary tract infection. This study was carried out to assess the value of prophylactic treatment with methenamine hippurate after routine gynecologic surgery.
METHODS: This was a prospective, randomized, double-blind, placebo-controlled clinical trial comprising 145 patients undergoing routine gynecologic laparotomy or vaginal plastic surgery using a Foley catheter for 24 h. Antibiotics were not used. Subjects received 1 g Hiprex or placebo twice daily for 5 days. Urine was cultured preoperatively, at catheter removal, and 2 days later. Patients with positive cultures were not given antibiotics unless they were symptomatic. The follow-up period was 1 month. STATISTICS: The chi-square test, Fisher exact test, and t-test were used with level of significance at 0.05, and odds ratios with 95% confidence intervals were calculated.
RESULTS: Asymptomatic bacteriuria was diagnosed in 36 cases (50.0%) in the placebo group and 22 cases (30.1%) in the methenamine group (p = 0.02). Urinary tract infection was diagnosed in 10 cases (13.9%) in the placebo group and two cases (2.7%) in the methenamine group (p = 0.03). There were few adverse events.
CONCLUSIONS: Prophylactic treatment with methenamine hippurate significantly reduces the incidence of postoperative bacteriuria and urinary tract infection.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12174159     DOI: 10.1080/j.1600-0412.2002.810810.x

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  7 in total

1.  Prophylactic antibiotics to prevent urinary tract infection during clean intermittent self-catheterization (CISC) for management of voiding dysfunction after prolapse and incontinence surgery: a decision analysis.

Authors:  Gary Sutkin; Jerry L Lowder; Kenneth J Smith
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2009-04-10

Review 2.  How to Prevent Catheter-Associated Urinary Tract Infections: A Reappraisal of Vico's Theory-Is History Repeating Itself?

Authors:  Stefania Musco; Alessandro Giammò; Francesco Savoca; Luca Gemma; Paolo Geretto; Marco Soligo; Emilio Sacco; Giulio Del Popolo; Vincenzo Li Marzi
Journal:  J Clin Med       Date:  2022-06-14       Impact factor: 4.964

Review 3.  Prophylactic antibiotics for preventing infection after continence surgery in women with stress urinary incontinence.

Authors:  Teerayut Temtanakitpaisan; Pranom Buppasiri; Pisake Lumbiganon; Malinee Laopaiboon; Siwanon Rattanakanokchai
Journal:  Cochrane Database Syst Rev       Date:  2022-03-29

Review 4.  Methenamine hippurate for preventing urinary tract infections.

Authors:  Bon San B Lee; Tushar Bhuta; Judy M Simpson; Jonathan C Craig
Journal:  Cochrane Database Syst Rev       Date:  2012-10-17

Review 5.  Evaluation of methenamine for urinary tract infection prevention in older adults: a review of the evidence.

Authors:  Amy Chwa; Kevin Kavanagh; Sunny Anne Linnebur; Danielle R Fixen
Journal:  Ther Adv Drug Saf       Date:  2019-09-23

6.  Treatment of Recurrent Urinary Tract Infection Symptoms with Urinary Antiseptics Containing Methenamine and Methylene Blue: Analysis of Etiology and Treatment Outcomes.

Authors:  Carlos Romualdo Barbosa Gama; Manoel Antônio Gonçalves Pombo; Carlos Pereira Nunes; Gustavo Falcão Gama; Spyros G E Mezitis; Mendel Suchmacher Neto; Oscar Roberto Guimarães; Mauro Geller; Lisa Oliveira; Adenilson de Souza da Fonseca; Aline Sitnoveter; Gerson Goldwasser; Karin Soares Cunha; Luiz Guilherme Darrigo Junior
Journal:  Res Rep Urol       Date:  2020-12-15

Review 7.  Catheter-Associated Urinary Tract Infections: Current Challenges and Future Prospects.

Authors:  Glenn T Werneburg
Journal:  Res Rep Urol       Date:  2022-04-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.